General Dermatology Archives - Clinical Pain Advisor

papulopustular rosacea, close-up of the patient's cheek

Migraine & Headache

Risk of Migraine May Be Higher With Rosacea

July 16, 2021

Migraine may be more common in people with rosacea.

General Pain

FDA Issues Complete Response Letter for Burn Therapy NexoBrid

By

Brian Park, PharmD

July 6, 2021

NexoBrid is a topically administered, bromelain-based biological product containing a sterile mixture of proteolytic enzymes.

Chronic Pain

Calciphylaxis Prevention and Treatment Strategies

By

Amelia Hoelscher, MD

Jayci Givens

Maura Holcomb, MD

June 18, 2021

Calciphylaxis treatment should include a multimodal approach with a focus on supportive care, infection prevention, pain management, and wound healing.

General Pain

Wearing Mask 8 Hours Per Day Linked to Worsened Acne and Rosacea

By

Brandon May

June 4, 2021

Mask-related rosacea and acne (“maskne”) in untreated patients during lockdown was evaluated.

General Pain

Epidermolysis Bullosa: Treatment Challenges and Emerging Developments

By

Tori Rodriguez, MA, LPC, AHC

May 18, 2021

Even though it is often thought of as a skin condition, many forms of epidermolysis bullosa are truly multisystem disorders, which makes coordinating the care complex.

Musculoskeletal Pain

Pain Alone Does Not Confer Premature Mortality in Psoriatic Arthritis Patients

By

Lauren Biscaldi

April 30, 2021

The researchers investigated whether higher cumulative pain intensity is associated with an excess mortality risk in patients with psoriatic arthritis.

PRP platelet rich plasma scalp injection

General Pain

Ice Pack Compression, Vibration Anesthesia Device Reduce Pain During Scalp Injections

By

Colby Stong

April 23, 2021

Inexpensive, practical, and safe strategies to reduce patients’ pain level during inactivated PRP scalp injections are reviewed.

No single treatment for HS is effective in eradicating disease or preventing progression, but early recognition and treatment are critical to preventing further progression to severe disease that can have an impact on quality of life.8 Therapeutic goals for stage 1 HS in young patients are to reduce pain and inflammation and prevent scarring and disease progression through multimodal management. Topical disinfectants are generally considered ineffective.4 Topical antibiotics are the therapy of choice for mild-to-moderate disease, with the introduction of oral antibiotics where topical formulations are inadequate.4 Once the disease has progressed, biologic disease modifying antirheumatic therapies, laser therapy, and surgery may have some benefit.8 Evidence supporting the use of intravenous infliximab in Hurley stage 2 and 3 HS has not been adequate enough to recommend it.9 Treatment of HS requires an aggressive multidisciplinary effort that involves antibiotic treatment, multimodal anti-inflammatory therapy and hormonal therapies, dietary and lifestyle modifications, and avoidance of physical trauma to the affected regions, which can lead to rupture of abscesses, along with early surgical unroofing and debridement. Additionally, because of the stigma and psychological distress, counseling for possible depression and to support coping skills is also recommended.3

General Pain

Evidence-Based Comorbidity Screening for Patients With Hidradenitis Suppurativa

By

Brandon May

April 1, 2021

To improve long-term outcomes for patients with HS, evidence-based screening recommendations to help clinicians recognize and treat 30 comorbid conditions have been developed.

Treatments

Ixekizumab Treatment Improves Psoriasis Symptoms

December 1, 2016

Ixekizumab led to significant improvements in itch severity, skin pain, and bothersomeness.